Is UniQure (QURE) One of the Promising Stocks to Buy Under $50?

UniQure (NASDAQ:QURE) is one of the promising stocks to buy under $50. On December 11, Stifel lowered the firm’s price target on uniQure to $40 from $50, while maintaining a Buy rating on the shares. In its 2026 biotech sector outlook, Stifel conducted a comprehensive review of its coverage universe. This refreshed diligence resulted in several adjustments to financial models, earnings estimates, and price targets across the group.

Mizuho analyst Uy Ear also reduced the price target for UniQure (NASDAQ:QURE) to $33 from $60 earlier on December 8, while maintaining an Outperform rating on the shares. This adjustment followed a major regulatory shift: the FDA informed the company that current data from its Phase I/II studies for AMT-130 (a Huntington’s disease gene therapy) likely lacks the primary evidence required for a BLA.

Consequently, Mizuho lowered its projected probability of success and delayed the expected market launch of AMT-130 by one year. Despite these hurdles, the firm remained optimistic about the therapy’s long-term potential, noting that a follow-up Type A meeting with the FDA is scheduled for Q1 2026 to establish a new path forward.

UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.